Clareo Health | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fasting lipoprotein(a) (Lp(a)) 50 mg/dL or more at screening 1
Fasting Low-density lipoprotein-cholesterol (LDL-C) 100 mg/dL or more at screening 1
Lipid lowering therapy including statin dose unchanged for at least 8 weeks prior to screening
Target-to-background ratio (TBR) maximum higher than 1.6 (either right, left carotid or thoracic aorta) on fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT).
You may not be if
Currently receiving, or less than 4 weeks since receiving, treatment in another investigational device or drug study(ies), or participating in other investigational procedures
Known diagnosis of diabetes mellitus or screening fasting serum glucose ≥ 126 mg/dL or hemoglobin A1C (HbA1C) ≥ 6.5%
Subject with a history of homozygous familial hypercholesterolemia
History of a Cardiovascular event
Subject currently undergoing lipid apheresis
Known contraindications or limitations to FDG-PET/ CT (scanner weight limit, devices that can cause image artifacts, or carotid/aortic stents/grafts
Subject has had exposure to investigational drugs targeting Lp(a) within the last 12 months, prior to Screening
